Tagged with Adium

LatAm From the perspective of international pharmaceuticals developers, Latin America can be considered a region of exceptional potential owing to solid market fundamentals and significant untapped opportunities. “I am convinced that we are poised to become among the most dynamic regions for growth momentum globally driven by multiple factors: among them…

LatAm When it comes to pharmaceutical exports, Latin America has historically been confined to the margins of the global life science industry. In 2023, the region accounted for a mere one percent of worldwide pharmaceutical exports, down from 1.97 percent a decade earlier, despite housing over eight percent of the world’s…

LatAm Adium is one of Latin America’s most expansive pharmaceutical groups, operating across 18 countries with a workforce of 7,000 employees. The organisation has unified its brand identity across the region whilst establishing world-class infrastructure and capabilities spanning oncology, rare diseases, and speciality therapeutics. The company´s strategic vision centres on positioning…

Mexico Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent according to a 2023 CANIFARMA and INEGI study. That makes it, on paper, appear a highly attractive sector for investment,…

Mexico Adium Mexico, recently rebranded to reflect the identity of the broader Adium Group, represents no less than 25 percent of the LatAm group’s sales. General Director José Miguel Fonken Quiroga shares the affiliate’s number one status, stellar growth, vast portfolio, and plans to expand into OTC and vaccines. Fonkel also…